Ferumoxytol and iron sucrose have comparable safety and efficacy in the treatment of iron deficiency anemia in patients with chronic kidney disease, according to the results of a head-to-head randomized, controlled trial.
The trial, by Iain C. Macdougall, MD, of King’s College Hospital in London, and colleagues included 162 anemic CKD patients randomly assigned to receive either ferumoxytol (80 patients, two 510 mg injections) or iron sucrose (82 patients, 1.0 g iron sucrose administered either as a slow injection or infusion).
Overall, the treatment arms experienced similar increases in hemoglobin from baseline to week 5, the researchers reported in the Clinical Journal of the American Society of Nephrology. The rate of adverse events (AEs) was 48% for ferumoxytol and 65% for iron sucrose. The rate of AEs related to treatment was 10% and 16%, respectively. The rate of serious AEs was 9% and 7%, respectively, and the rate of serious AEs related to treatment was 1% and 1%, respectively.